Dublin, Ireland, 11th April 2007
AGI Therapeutics, plc Financial results for the twelve months ended 31 December 2006
AGI Therapeutics plc ("AGI" or the "Company"), a speciality pharmaceutical company focused on gastrointestinal drug products, today reports audited financial results for the twelve months ended 31 December 2006. > Learn More
(The full annual report is available under Publications in the Investors section.)
AGI Therapeutics plc FDA approval to file IND for Arverapamil Phase III study
AGI Therapeutics plc ("AGI" or the "Company") (AIM, IEX: AGI), a speciality pharmaceutical company focused on gastrointestinal drug products, today announces that it has concluded a successful pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) for arverapamil, (AGI-003), AGI's lead product for irritable bowel syndrome (IBS). > Learn More
AGI Therapeutics plc - Strengthens management team
AGI Therapeutics plc ("AGI" or the "Company") (AIM, IEX: AGI), a speciality pharmaceutical company focused on gastrointestinal drug products, today announces the appointment of two new Vice Presidents to its management team. > Learn More
AGI Therapeutics plc - Product update and outlook for 2007
AGI Therapeutics plc ("AGI" or the "Company") (AIM, IEX: AGI), a speciality pharmaceutical company focused on gastrointestinal drug products, today announces continued progress on key development programmes and outlines its plans for these programmes in 2007. Following on from the reporting of clinical results on 4 of its products in 2006 and the recent reporting, earlier this month, of clinical results on its other 2 products, AGI is now in a position to map the next key steps in progressing five of the original six products in its pipeline into further clinical development. > Learn More
Preliminary clinical data for mecamylamine (AGI-004) and arbaclofen (AGI-006)
AGI Therapeutics plc ("AGI" or the "Company") (AIM, IEX: AGI), a speciality pharmaceutical company focused on gastrointestinal drug products, today announces preliminary results of Phase II studies for mecamylamine (AGI-004, for functional diarrhoea) and arbaclofen (AGI-006 for functional dyspepsia). The results of these studies follow the reporting last year of positive results for other AGI products in development. > Learn More
AGI Therapeutics plc appoints strong Medical Advisory Panel.
AGI Therapeutics plc ("AGI" or the "Company") (AIM, IEX: AGI), a speciality pharmaceutical company focused on gastrointestinal drug products, today announces the appointment of a Medical Advisory Panel of international experts in the field of gastroenterology. > Learn More
AGI Therapeutics announces preliminary results of phase II trial of espindolol (AGI-001) in irritable bowel syndrome.
AGI Therapeutics plc (AIM, IEX: AGI, "AGI" or the "Company"), a speciality pharmaceutical company focused on gastrointestinal (GI) drug products, today announces the preliminary results of a phase II trial of the Company's espindolol (AGI-001) product candidate for the treatment of irritable bowel syndrome (IBS). > Learn More
AGI Therapeutics plc signs $19 million exclusive license agreement with Axcan Pharma for delayed/controlled release omeprazole.
AGI Therapeutics plc ("AGI" or the "Company") (AIM, IEX: AGI), a speciality pharmaceutical company focused on gastrointestinal drug products, today announces that it has entered into an exclusive license agreement with Axcan Pharma, Inc. ("Axcan") (NASDAQ: AXCA, TSX: AXP) for North American rights to AGI's delayed/controlled release omeprazole formulation, AGI-010. Axcan is a leading marketer of pharmaceutical products for gastrointestinal diseases and disorders in North America and Europe, with revenues in 2005 of over US $250 million. > Learn More
AGI Therapeutics, plc Interim financial results for the six months ended 30 June, 2006.
AGI Therapeutics plc ("AGI" or the "Company"), a speciality pharmaceutical company focused on gastrointestinal drug products, today reports interim financial results for the six months ended 30 June, 2006. > Download results PDF
AGI Therapeutics plc Appoints Chris Blackwell as Non-Executive Director.
AGI Therapeutics plc ("AGI" or the "Company"), a speciality pharmaceutical company focused on gastrointestinal drug products, today announces the appointment of Dr. Chris Blackwell, Chief Executive of Vectura Group plc, to its Board of Directors. > Learn More
AGI Therapeutics Announces Preliminary Results of Phase II Trials for Gastrointestinal Disorders.
AGI Therapeutics plc (AIM, IEX: AGI, "AGI" or the "Company"), a speciality pharmaceutical company focused on gastrointestinal (GI) drug products, today announces the preliminary results of two Phase II trials of its arverapamil (AGI-003) and espindolol (AGI-001) product candidates. > Learn More
AGI Therapeutics plc appoints Dr. David Young as President of US Operations.
AGI Therapeutics plc (AIM, IEX: AGI), a speciality pharmaceutical company focused on gastrointestinal (GI) drug products, today announces the appointment of David Young, Pharm.D. Ph.D., as President of US Operations and Executive Member of the Board of AGI. The appointment is effective from 5 June 2006. > Learn More
AGI Therapeutics plc announces appointment of Chief Financial Officer.
AGI Therapeutics plc ("AGI" or the "Company"), a speciality pharmaceutical company focused on gastrointestinal drug products, today announces the appointment of Mr. David G. Kelly as director and Chief Financial Officer. Mr. Kelly's appointment will be effective as of 2 May 2006. > Learn More
AGI Therapeutics plc Financial results for the year ended 31 December 2005.
AGI Therapeutics plc ("AGI" or the "Company"), a speciality pharmaceutical company focused on gastrointestinal drug products, today reported the audited financial results for AGI Therapeutics Research Limited, formerly AGI Therapeutics Ltd, for the year ended 31 December 2005. AGI Therapeutics Research Limited is the operating subsidiary of AGI Therapeutics plc which was created as a holding entity prior to the Company's recent flotation. > Learn More
AGI Therapeutics plc reports results of clinical studies for two product candidates.
AGI Therapeutics plc ("AGI" or the "Company"), a speciality pharmaceutical company focused on gastrointestinal drug products, today reported the outcome of a clinical study on its AGI-022 product candidate and preliminary data from a clinical study on its AGI-010 product candidate. Both product candidates are modified release oral formulations of existing drugs used to treat gastrointestinal diseases. > Learn More
AGI Therapeutics, plc Financial results for the twelve months ended 31 December 2006
AGI Therapeutics plc ("AGI" or the "Company"), a speciality pharmaceutical company focused on gastrointestinal drug products, today reports audited financial results for the twelve months ended 31 December 2006. > Learn More
(The full annual report is available under Publications in the Investors section.)
Dublin, Ireland, 11th April 2007
AGI Therapeutics plc FDA approval to file IND for Arverapamil Phase III study
AGI Therapeutics plc ("AGI" or the "Company") (AIM, IEX: AGI), a speciality pharmaceutical company focused on gastrointestinal drug products, today announces that it has concluded a successful pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) for arverapamil, (AGI-003), AGI's lead product for irritable bowel syndrome (IBS). > Learn More
Dublin, Ireland, 12th March 2007
AGI Therapeutics plc - Strengthens management team
AGI Therapeutics plc ("AGI" or the "Company") (AIM, IEX: AGI), a speciality pharmaceutical company focused on gastrointestinal drug products, today announces the appointment of two new Vice Presidents to its management team. > Learn More
Dublin, Ireland, 15th February 2007
AGI Therapeutics plc - Product update and outlook for 2007
AGI Therapeutics plc ("AGI" or the "Company") (AIM, IEX: AGI), a speciality pharmaceutical company focused on gastrointestinal drug products, today announces continued progress on key development programmes and outlines its plans for these programmes in 2007. Following on from the reporting of clinical results on 4 of its products in 2006 and the recent reporting, earlier this month, of clinical results on its other 2 products, AGI is now in a position to map the next key steps in progressing five of the original six products in its pipeline into further clinical development. > Learn More
Dublin, Ireland, 1st February 2007
Preliminary clinical data for mecamylamine (AGI-004) and arbaclofen (AGI-006)
AGI Therapeutics plc ("AGI" or the "Company") (AIM, IEX: AGI), a speciality pharmaceutical company focused on gastrointestinal drug products, today announces preliminary results of Phase II studies for mecamylamine (AGI-004, for functional diarrhoea) and arbaclofen (AGI-006 for functional dyspepsia). The results of these studies follow the reporting last year of positive results for other AGI products in development. > Learn More
Dublin, Ireland, 22nd January 2007
AGI Therapeutics plc appoints strong Medical Advisory Panel.
AGI Therapeutics plc ("AGI" or the "Company") (AIM, IEX: AGI), a speciality pharmaceutical company focused on gastrointestinal drug products, today announces the appointment of a Medical Advisory Panel of international experts in the field of gastroenterology. > Learn More
Dublin, Ireland, 29 September, 2006
AGI Therapeutics announces preliminary results of phase II trial of espindolol (AGI-001) in irritable bowel syndrome.
AGI Therapeutics plc (AIM, IEX: AGI, "AGI" or the "Company"), a speciality pharmaceutical company focused on gastrointestinal (GI) drug products, today announces the preliminary results of a phase II trial of the Company's espindolol (AGI-001) product candidate for the treatment of irritable bowel syndrome (IBS). > Learn More
Dublin, Ireland, 27th September 2006
AGI Therapeutics plc signs $19 million exclusive license agreement with Axcan Pharma for delayed/controlled release omeprazole.
AGI Therapeutics plc ("AGI" or the "Company") (AIM, IEX: AGI), a speciality pharmaceutical company focused on gastrointestinal drug products, today announces that it has entered into an exclusive license agreement with Axcan Pharma, Inc. ("Axcan") (NASDAQ: AXCA, TSX: AXP) for North American rights to AGI's delayed/controlled release omeprazole formulation, AGI-010. Axcan is a leading marketer of pharmaceutical products for gastrointestinal diseases and disorders in North America and Europe, with revenues in 2005 of over US $250 million. > Learn More
Dublin, Ireland, 7th September 2006
AGI Therapeutics, plc Interim financial results for the six months ended 30 June, 2006.
AGI Therapeutics plc ("AGI" or the "Company"), a speciality pharmaceutical company focused on gastrointestinal drug products, today reports interim financial results for the six months ended 30 June, 2006. > Download results PDF
Dublin, Ireland, 13th July 2006
AGI Therapeutics plc Appoints Chris Blackwell as Non-Executive Director.
AGI Therapeutics plc ("AGI" or the "Company"), a speciality pharmaceutical company focused on gastrointestinal drug products, today announces the appointment of Dr. Chris Blackwell, Chief Executive of Vectura Group plc, to its Board of Directors. > Learn More
Dublin, Ireland, 7th June 2006
AGI Therapeutics Announces Preliminary Results of Phase II Trials for Gastrointestinal Disorders.
AGI Therapeutics plc (AIM, IEX: AGI, "AGI" or the "Company"), a speciality pharmaceutical company focused on gastrointestinal (GI) drug products, today announces the preliminary results of two Phase II trials of its arverapamil (AGI-003) and espindolol (AGI-001) product candidates. > Learn More
Dublin, Ireland, 15th May 2006
AGI Therapeutics plc appoints Dr. David Young as President of US Operations.
AGI Therapeutics plc (AIM, IEX: AGI), a speciality pharmaceutical company focused on gastrointestinal (GI) drug products, today announces the appointment of David Young, Pharm.D. Ph.D., as President of US Operations and Executive Member of the Board of AGI. The appointment is effective from 5 June 2006. > Learn More
Dublin, Ireland, April 20th 2006
AGI Therapeutics plc announces appointment of Chief Financial Officer.
AGI Therapeutics plc ("AGI" or the "Company"), a speciality pharmaceutical company focused on gastrointestinal drug products, today announces the appointment of Mr. David G. Kelly as director and Chief Financial Officer. Mr. Kelly's appointment will be effective as of 2 May 2006. > Learn More
Dublin, Ireland, April 20th 2006
AGI Therapeutics plc Financial results for the year ended 31 December 2005.
AGI Therapeutics plc ("AGI" or the "Company"), a speciality pharmaceutical company focused on gastrointestinal drug products, today reported the audited financial results for AGI Therapeutics Research Limited, formerly AGI Therapeutics Ltd, for the year ended 31 December 2005. AGI Therapeutics Research Limited is the operating subsidiary of AGI Therapeutics plc which was created as a holding entity prior to the Company's recent flotation. > Learn More
Dublin, Ireland, 29th March 2006
AGI Therapeutics plc reports results of clinical studies for two product candidates.
AGI Therapeutics plc ("AGI" or the "Company"), a speciality pharmaceutical company focused on gastrointestinal drug products, today reported the outcome of a clinical study on its AGI-022 product candidate and preliminary data from a clinical study on its AGI-010 product candidate. Both product candidates are modified release oral formulations of existing drugs used to treat gastrointestinal diseases. > Learn More
Dublin, Ireland, 27 February 2006
AGI Therapeutics plc Admission to trading on AIM and IEX €42.5 Million Placing.
AGI Therapeutics plc ("AGI" or the "Company"), a specialty pharmaceuticals company focused on gastrointestinal drug products, announces that admission to trading will become effective, and dealings in its ordinary shares will commence today on the AIM market of the London Stock Exchange and the IEX market of the Irish Stock Exchange (“Admission”).
> Learn More
